These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15313395)

  • 1. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system.
    Bikfalvi A
    Biochem Pharmacol; 2004 Sep; 68(6):1017-21. PubMed ID: 15313395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
    Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
    Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
    Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor.
    Zilberberg L; Shinkaruk S; Lequin O; Rousseau B; Hagedorn M; Costa F; Caronzolo D; Balke M; Canron X; Convert O; Laïn G; Gionnet K; Goncalvès M; Bayle M; Bello L; Chassaing G; Deleris G; Bikfalvi A
    J Biol Chem; 2003 Sep; 278(37):35564-73. PubMed ID: 12837752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules.
    Bikfalvi A; Gimenez-Gallego G
    Semin Thromb Hemost; 2004 Feb; 30(1):137-44. PubMed ID: 15034805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma.
    Bello L; Lucini V; Costa F; Pluderi M; Giussani C; Acerbi F; Carrabba G; Pannacci M; Caronzolo D; Grosso S; Shinkaruk S; Colleoni F; Canron X; Tomei G; Deleris G; Bikfalvi A
    Clin Cancer Res; 2004 Jul; 10(13):4527-37. PubMed ID: 15240545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
    Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
    Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
    Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions.
    Gonçalves M; Estieu-Gionnet K; Berthelot T; Laïn G; Bayle M; Canron X; Betz N; Bikfalvi A; Déléris G
    Pharm Res; 2005 Aug; 22(8):1411-21. PubMed ID: 16078152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet factor 4: an inhibitor of angiogenesis.
    Bikfalvi A
    Semin Thromb Hemost; 2004 Jun; 30(3):379-85. PubMed ID: 15282661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors.
    Sun J; Wang DA; Jain RK; Carie A; Paquette S; Ennis E; Blaskovich MA; Baldini L; Coppola D; Hamilton AD; Sebti SM
    Oncogene; 2005 Jul; 24(29):4701-9. PubMed ID: 15897913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.